Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
PLIANT THERAPEUTICS, INC.Pliant Therapeutics Reports $210.3 Million Net Loss and Nil Revenue for 2024
Fractyl Health, Inc.Fractyl Health Reports $68.7M Net Loss in 2024, Announces Strategic Reprioritization
ACM Research, Inc.ACM Research Reports 40.2% Revenue Increase to $782.1 Million for Fiscal Year 2024
BIODESIX INCBiodesix Reports 45% Revenue Growth to $71.3 Million for 2024
WESBANCO INCWesbanco Reports $141.4 Million Net Income for 2024, Completes Premier Financial Acquisition
Sunnova Energy International Inc.Sunnova Energy Reports $367.9 Million Net Loss and 17% Revenue Growth for 2024
TG THERAPEUTICS, INC.TG Therapeutics Reports $23.38 Million Net Income for Fiscal Year 2024, Driven by BRIUMVI Revenue Growth
MeiraGTx Holdings plcMeiraGTx Reports $147.8 Million Net Loss for 2024, Highlights Clinical Advancements and Strategic Collaborations
NEWMARK GROUP, INC.Newmark Group Reports $2.7 Billion Revenue for Fiscal Year 2024, Driven by Growth in All Revenue Streams
SOUTHERN COPPER CORP/Southern Copper Corporation Reports Record Net Sales of $11.4 Billion for 2024
Hilton Grand Vacations Inc.Hilton Grand Vacations Reports $4.98 Billion Revenue, $47 Million Net Income for 2024
OPKO HEALTH, INC.OPKO Health Reports $152.1 Million Loss and 17% Revenue Decline for 2024
Mersana Therapeutics, Inc.Mersana Therapeutics Reports $69.2 Million Net Loss for 2024, Collaboration Revenue Increases
PMV Pharmaceuticals, Inc.PMV Pharmaceuticals Reports $58.7 Million Net Loss for 2024, Advances Rezatapopt in Clinical Trials
Edgewise Therapeutics, Inc.Edgewise Therapeutics Reports $133.8 Million Net Loss for 2024, Driven by Increased Operating Expenses
CLOVER HEALTH INVESTMENTS, CORP. /DEClover Health Reports $46.3 Million Net Loss for 2024, Revenue Increases to $1.37 Billion
ImmunityBio, Inc.ImmunityBio Reports $413.6 Million Net Loss for 2024, Significant Revenue Growth from ANKTIVA
Repare Therapeutics Inc.Repare Therapeutics Reports $84.7 Million Net Loss for 2024, Revenue Increases to $53.5 Million
ArriVent Biopharma, Inc.ArriVent Biopharma Reports $80.5 Million Net Loss for 2024, Increases R&D Spending
OCULAR THERAPEUTIX, INCOcular Therapeutix Reports $193.5 Million Net Loss for 2024, Increases DEXTENZA Sales by 9.7%
Hut 8 Corp.Hut 8 Corp. Reports $162.4 Million Revenue and $331.9 Million Net Income for 2024
Apogee Therapeutics, Inc.Apogee Therapeutics Reports $182.1 Million Net Loss for Year Ended December 31, 2024
REDWOOD TRUST INCRedwood Trust Reports $54M Net Income for 2024, Significant Revenue Increases
Atea Pharmaceuticals, Inc.Atea Pharmaceuticals Reports $168.4 Million Net Loss for 2024, Plans Phase 3 Trials for HCV Treatment
KINETA, INC./DEKineta, Inc. Reports $17.1 Million Net Loss and Explores Strategic Alternatives Amid Financial Challenges